AC Immune, a clinical-stage biopharmaceutical precision medicine company for neurodegenerative diseases, announced it’s acquisition of Affiris’s portfolio of therapeutics targeting alphasynuclein (a-syn), notably Affiris PD01, a clinically-validated active vaccine candidate for the treatment
Tags :Vera Naegeli
Approximately 30,000 customers of CSS Versicherung will transfer to Zürich Versicherungs, as well as 68 employees